Back to GetFilings.com



Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________________

FORM 10-Q

     
(Mark One)    
[X]   Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
    For the quarterly period ended March 31, 2003
    or
[   ]   Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
    For the transition period from      to      

Commission file number 0-18053

LASERSCOPE

(Exact name of Registrant as Specified in Its Charter)

     
CALIFORNIA
(State or Other Jurisdiction
of Incorporation or Organization)
  77-0049527
(I.R.S. Employer Identification No.)
 
3070 ORCHARD DRIVE, SAN JOSE, CALIFORNIA 95134-2011
(Address of Principal Executive Offices)

Registrant’s Telephone Number, Including Area Code: (408) 943-0636

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes  [X]     No  [   ]

Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Act). YES  [   ]     NO  [X]

The number of shares of Registrant’s common stock issued and outstanding as of April 30, 2003 was 17,162,275.

 


TABLE OF CONTENTS

PART I.     FINANCIAL INFORMATION.
Item 1.     Financial Statements. (unaudited)
Condensed Consolidated Balance Sheets
Condensed Consolidated Statements of Operations
Condensed Consolidated Statements of Cash Flows
Notes to Condensed Consolidated Financial Statements:
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
Results of Operations.
Liquidity and Capital Resources.
Risk Factors.
Item 3. Quantitative and Qualitative Disclosures About Market Risk.
Item 4. Controls and Procedures.
PART II. OTHER INFORMATION
Item 1. Legal Proceedings.
Item 2. Changes in Securities and Use of Proceeds.
Item 3. Defaults upon Senior Securities.
Item 4. Submission of Matters to a Vote of Security Holders.
Item 5. Other Information.
Item 6. Exhibits and Reports on Form 8-K.
SIGNATURES
EXHIBIT 99.1
EXHIBIT 99.2


Table of Contents

TABLE OF CONTENTS

                     
        Page
       
PART I. FINANCIAL INFORMATION     3  
Item 1.   Financial Statements (unaudited)     3  
    Condensed Consolidated Balance Sheets     3  
    Condensed Consolidated Statements of Operations     4  
    Condensed Consolidated Statements of Cash Flows     5  
    Notes to Condensed Consolidated Financial Statements     6  
Item 2.   Management’s Discussion and Analysis of Financial Condition and Results of Operations     10  
    Results of Operations     11  
    Liquidity and Capital Resources     12  
    Risk Factors     14  
Item 3.   Quantitative and Qualitative Disclosures About Market Risk     22  
Item 4.   Controls and Procedures     22  
             
PART II. OTHER INFORMATION     23  
Item 1.   Legal Proceedings     23  
Item 2.   Changes in Securities and Use of Proceeds     23  
Item 3.   Defaults upon Senior Securities     23  
Item 4.   Submission of Matters to a Vote of Security Holders     23  
Item 5.   Other Information     23  
Item 6.   Exhibits and Reports on Form 8-K     24  
             
SIGNATURES     25  

2


Table of Contents

PART I.     FINANCIAL INFORMATION.

Item 1.     Financial Statements.

Laserscope
Condensed Consolidated Balance Sheets
(unaudited)

                       
          March 31,   December 31,
(thousands)   2003   2002

 
 
Assets
               
Current assets:
               
 
Cash and cash equivalents
  $ 4,754     $ 4,661  
 
Accounts receivable, net
    10,963       10,287  
 
Inventories, net
    10,281       10,445  
 
Other current assets
    806       1,027  
 
   
     
 
   
Total current assets
    26,804       26,420  
Property and equipment, net
    1,631       1,808  
Goodwill
    655       655  
Other assets
    246       280  
 
   
     
 
     
Total assets
  $ 29,336     $ 29,163  
 
   
     
 
Liabilities and Shareholders’ Equity
               
Current liabilities:
               
 
Accounts payable
  $ 3,551     $ 3,989  
 
Accrued compensation
    1,918       2,033  
 
Deferred revenue
    1,637       1,408  
 
Convertible subordinated debentures, current portion
    232       147  
 
Other current liabilities
    3,399       3,191  
 
   
     
 
   
Total current liabilities
    10,737       10,768  
 
   
     
 
Convertible subordinated debentures, net of current portion
    2,768       2,853  
Obligations under capital leases
    47       60  
 
   
     
 
   
Total long-term liabilities
    2,815       2,913  
 
   
     
 
Contingencies (Note 7)
               
Shareholders’ equity:
               
 
Common stock
    56,096       55,915  
 
Accumulated deficit
    (39,384 )     (39,519 )
 
Accumulated other comprehensive loss
    (803 )     (789 )
 
Notes receivable from shareholders
    (125 )     (125 )
 
   
     
 
     
Total shareholders’ equity
    15,784       15,482  
 
   
     
 
     
Total liabilities and shareholders’ equity
  $ 29,336     $ 29,163  
 
   
     
 

See Accompanying Notes to Condensed Consolidated Financial Statements

3


Table of Contents

Laserscope
Condensed Consolidated Statements of Operations
(Unaudited)

                       
          Three months ended
          March 31,
         
(thousands, except per share amounts)   2003   2002

 
 
 
Net revenue
  $ 12,456     $ 9,420  
 
Cost of sales
    6,191       4,799  
 
   
     
 
 
Gross margin
    6,265       4,621  
 
   
     
 
 
Operating expenses:
               
   
Research and development
    1,008       1,016  
   
Selling, general and administrative
    5,064       3,547  
 
   
     
 
     
Total operating expenses
    6,072       4,563  
 
   
     
 
 
Operating income
    193       58  
 
Interest and other expenses
    (36 )     (90 )
 
   
     
 
 
Income (loss) before income taxes
    157       (32 )
 
Provision for income taxes
    22       15  
 
   
     
 
 
Net income (loss)
  $ 135     $ (47 )
 
   
     
 
Basic and diluted net loss per share
  $ 0.01     $ 0.00  
 
   
     
 
Shares used in basic per share calculations
    16,899       16,155  
 
   
     
 
Shares used in diluted per share calculations
    18,858       16,155  
 
   
     
 

See Accompanying Notes to Condensed Consolidated Financial Statements

4


Table of Contents

Laserscope
Condensed Consolidated Statements of Cash Flows
(Unaudited)

                       
          Three Months Ended
          March 31,
         
(thousands)   2003   2002

 
 
Cash flows from operating activities:
               
 
Net income (loss)
  $ 135     $ (47 )
 
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
               
   
Depreciation and amortization
    319       318  
   
Changes in assets and liabilities:
               
     
Accounts receivable, net
    (698 )     (742 )
     
Inventories
    185       466  
     
Other current assets
    222       65  
     
Accounts payable
    (413 )     (294 )
     
Accrued compensation
    (116 )     (56 )
     
Deferred revenue
    229       77  
     
Other current liabilities
    220       121  
 
   
     
 
Net cash provided by (used in) operating activities
    83       (92 )
 
   
     
 
Cash flows from investing activities:
               
 
Acquisition of property and equipment
    (107 )     (187 )
 
   
     
 
Net cash used in investing activities
    (107 )     (187 )
 
   
     
 
Cash flows from financing activities:
               
 
Payments on obligations under capital leases
    (72 )     (52 )
 
Proceeds from the sale of common stock under stock plans
    182       203  
 
Proceeds from bank loans
    200       3,320  
 
Repayment of bank loans
    (200 )     (3,355 )
 
   
     
 
Net cash provided by financing activities
    110       116  
 
   
     
 
Effect of exchange rate changes on cash
    7       (36 )
Net increase (decrease) in cash and cash equivalents
    93       (199 )
Cash and cash equivalents, beginning of period
    4,661       3,408  
 
   
     
 
Cash and cash equivalents, end of period
  $ 4,754     $ 3,209  
 
   
     
 
Supplemental disclosure of cash flow information:
               
   
Cash paid during the period for:
               
     
Interest
  $ 67     $ 77  
     
Income taxes
  $ 8     $ 3  

See Accompanying Notes to Condensed Consolidated Financial Statements

5


Table of Contents

Laserscope Notes to Unaudited Condensed Consolidated Financial Statements:

1.    Basis of presentation

The accompanying unaudited condensed consolidated financial statements include Laserscope (the “Company,” “management,” “we,” “us,” “our”) and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated. While the financial information in this report is unaudited, in the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position and results of operations as of and for the periods indicated have been recorded. We suggest that these consolidated financial statements be read in conjunction with the consolidated financial statements and notes for the year ended December 31, 2002 included in the Company’s annual report on Form 10-K for the year ended December 31, 2002. The results of operations for the three month period ended March 31, 2003 are not necessarily indicative of the results expected for the full year.

2.   Accounting for Stock-Based Compensation

The Company has adopted SFAS No. 148, “Accounting for Stock-Based Compensation, Transition and Disclosure.” The Company accounts for stock-based employee compensation arrangements in accordance with the provisions of Accounting Principles Board Opinion No. 25, “Accounting for Stock Issued to Employees” (“APB No. 25”) and its related interpretations and has elected to follow the disclosure-only provisions of Statement of Financial Accounting Standards No. 123, “Accounting for Stock-Based Compensation” (“SFAS No. 123”). Under APB No. 25, compensation expense is based on the difference, if any, on the date of the stock option grant between the fair value of the Company’s stock and the exercise price of the stock option.

Had compensation cost for stock-based employee compensation arrangements been determined based on the fair value at the date of the awards consistent with the provisions of SFAS No. 123, the impact on Laserscope’s net income (loss) would be as follows (in thousands, except per share data):

                   
      Three months ended
      March 31,
     
      2003   2002
     
 
Net income (loss) attributable to common stockholders:
               
 
As reported
  $ 135     $ (47 )
 
Add: Stock-based compensation expense included in reported net loss
          3  
 
Deduct: Total stock-based compensation expense determined under fair value based method for all awards
    (240 )     (175 )
 
   
     
 
 
Pro forma net loss
  $ (105 )   $ (219 )
 
   
     
 
Net (income) loss per share:
               
 
Basic — as reported
  $ 0.01     $ 0.00  
 
   
     
 
 
Basic — pro forma
  $ (0.01 )   $ (0.01 )
 
   
     
 
 
Diluted — as reported
  $ 0.01     $ 0.00  
 
   
     
 
 
Diluted — pro forma
  $ (0.01 )   $ (0.01 )
 
   
     
 

6


Table of Contents

Laserscope accounts for equity instruments issued to non-employees in accordance with the provisions of SFAS No. 123 and Emerging Issues Task Force Issue No. 96-18, “Accounting for Equity Instruments That Are Issued to Other Than Employees for Acquiring, or in Conjunction with Selling, Goods or Services.”

3.   Inventories

Inventories were comprised of the following (in thousands):

                 
    March 31,   December 31,
    2003   2002
   
 
Sub-assemblies and purchased parts
  $ 4,643     $ 4,304  
Work-in-process
    3,151       3,340  
Finished goods
    2,487       2,801  
 
   
     
 
 
  $ 10,281     $ 10,445  
 
   
     
 

4.   Warranty and Service Contracts

Warranty

We have a direct field service organization that provides service for our products. We generally provide a twelve month warranty on our laser systems. After the warranty period, maintenance and support is provided on a service contract basis or on an individual call basis. Our warranties and premium service contracts provide for a “99.0% Uptime Guarantee” on our laser systems. Under provisions of this guarantee, we extend the term of the related warranty or service contract if specified system uptime levels are not maintained.

The Company currently provides for the estimated cost to repair or replace products under warranty at the time of sale. The cost estimate is based on warranty costs experienced in the prior 12 months, and the outstanding warranty liability is revalued on a quarterly basis.

             
Warranty Reserve (in thousands)   2003

 
Balance, December 31, 2002
  $ 1,127  
Add:
  Accruals for warranties issued in 2003     571  
   
Accruals related to pre-existing warranties
    14  
Less:
  Settlements made during the period     (427 )
 
   
 
Balance, March 31, 2003
  $ 1,285  
 
   
 

Service Contracts

Deferred service contract revenue is recognized on a pro rata basis over the period of the applicable service contract. Costs are recognized as incurred.

7


Table of Contents

           
Deferred Service Contract Revenue (in thousands)   2003

 
Balance, December 31, 2002
  $ 1,086  
Add:
       
 
Payments received
    925  
 
Costs incurred under service contracts
    442  
Less:
       
 
Revenue recognized
    (671 )
 
Settlements made during the period
    (442 )
 
   
 
Balance, March 31, 2003
  $ 1,340  
 
   
 

5.   Net income (loss) per share

Basic net income (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the period. Diluted net income (loss) per share is computed by giving effect to all dilutive potential common shares, including options, warrants, and convertible debentures. A reconciliation of the numerator and denominator used in the calculation of historical basic and diluted net income (loss) per share follows:

                   
      Three months ended
      March 31,
     
(thousands)   2003   2002

 
 
Numerator:
               
 
Net income (loss) used in computing basic and diluted net income (loss) per share
  $ 135     $ (47 )
 
   
     
 
Denominator:
               
 
Weighted average number of common shares outstanding used in computing basic net income (loss) per share
    16,899       16,155  
 
Add: Dilutive potential common shares used in computing dilutive net income (loss) per share
    1,959        
 
   
     
 
 
Total weighted-average number of shares used in computing diluted net income (loss) per share
    18,858       16,155  
 
   
     
 

The following outstanding options and warrants (prior to the application of the treasury stock method) and convertible debentures (on an as-converted basis) were excluded from the computation of diluted net income (loss) per common share for the periods ended March 31, 2003 and 2002 because including them would have had an antidilutive effect:

8


Table of Contents

                 
    Three months ended
    March 31,
   
(thousands)   2003   2002

 
 
Options to purchase common stock
    279       225  
Warrants to purchase common stock
    444       454  
Convertible debentures
    2,400       2,400  
 
   
     
 
 
    3,123       3,079  
 
   
     
 

6.   Comprehensive income (loss)

Total comprehensive income (loss) during the periods ended March 31, 2003 and 2002 consisted of (in thousands):

                         
    Three months ended
    March 31,
   
    2003   2002
   
 
Net income (loss)
  $ 135     $ (47 )
Translation adjustments
    (14 )     (90 )
 
   
     
 
Comprehensive income (loss)
  $ 121     $ (137 )
 
   
     
 

7.   Contingencies

The Company is at times a party to legal proceedings and claims arising in the ordinary course of its business. While it is not feasible to predict or determine the outcome of the actions brought against the Co